文献速递产科母胎医学

孕期常规巨细胞病毒筛查是否应采纳?不!

Is it time to adopt routine cytomegalovirus screening in pregnancy? No!
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-03-22

本文为临床观点文章,讨论孕期常规巨细胞病毒血清学筛查的利弊。作者指出,尽管高剂量伐昔洛韦可降低一线巨细胞病毒感染后的胎儿感染率,但现有证据尚不足以支持推行常规筛查,且筛查可能带来无胎儿感染确诊下的终止妊娠等危害。在证据充分前,应遵循多国卫生机构建议,重点推广孕期卫生措施的一级预防。

要点

  • 现有证据不足以支持孕期常规巨细胞病毒血清学筛查。
  • 筛查可能导致无胎儿感染确诊的终止妊娠等危害。
  • 当前应重点推广孕期卫生措施的一级预防。

核心结论

  • 在获得必要证据前,不应推行孕期常规巨细胞病毒筛查,应遵循多国卫生机构建议,重点推广孕期卫生措施的一级预防。

研究设计与样本

  • 本文为受邀临床观点文章,回顾相关证据并列出在判定孕期常规巨细胞病毒筛查获益是否大于危害前需采取的步骤。

主要发现

  • 近期随机试验发现,高剂量伐昔洛韦治疗可显著降低一线巨细胞病毒感染后的胎儿感染率。
  • 观察性研究曾发现孕早期每周两次给予超免疫球蛋白可降低母体原发巨细胞病毒感染后的胎儿感染率,但不同方案的随机试验未能重复该结果。
  • 伐昔洛韦和超免疫球蛋白治疗虽可能显著降低胎儿感染率,但并不能预防所有妊娠中严重的巨细胞病毒相关胎儿脑损伤。
  • 筛查可能增加无胎儿感染或后遗症诊断确认下的终止妊娠风险。
  • 孕期筛查与治疗策略的有效性依赖于较高的母体原发感染率,而原发感染率仅在巨细胞病毒血清患病率低的地区(如西欧)较高;在美国、芬兰和巴西等国,非原发母体感染造成大部分先天性巨细胞病毒健康负担,限制了孕期筛查的潜在影响。

临床怎么用

  • 当前应遵循多国卫生机构建议,聚焦于通过母体卫生防护措施推广一级预防。
  • 在证据充分前,不应启动孕期常规巨细胞病毒血清学筛查。

局限性

  • 部分证据来自单一干预试验和观察性研究,不足以支持推行适当的筛查规划。
  • 筛查与治疗策略的有效性受地区巨细胞病毒血清患病率和原发/非原发感染构成限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Congenital cytomegalovirus is caused by maternal primary or nonprimary infection during pregnancy and is a major preventable cause of neurodisability. The proposed strategies to reduce congenital cytomegalovirus include primary prevention with maternal hygiene measures and secondary prevention by serologic screening for detecting maternal primary infection. A recent randomized trial found that high-dose valaciclovir treatment resulted in a significant reduction in fetal infection after first-trimester maternal primary infection, leading to calls to start routine serologic screening in pregnancy. Previously, observational studies have found a reduction in fetal infection with after maternal primary cytomegalovirus infection when hyperimmune globulin is administered twice weekly during the first trimester of pregnancy; however, this has not been replicated in randomized trials that have used different regimens. Furthermore, some evidence from a single intervention trial and observational studies do not provide us with the necessary data required for rolling out an appropriate screening program. All screening tests may be associated with harm; in the case of congenital cytomegalovirus, there is the well-recognized potential for increasing terminations of pregnancy without diagnostic confirmation of fetal infection or sequelae. Although valaciclovir and hyperimmune globulin treatments may significantly reduce fetal infection rates, they do not prevent severe cytomegalovirus-related fetal brain damage in all pregnancies. Therefore, it is not clear that the offer of a prenatal intervention will provide sufficient reassurance to screen-positive women. In addition, the effectiveness of a prenatal screening and treatment strategy is predicated on a high rate of maternal primary infection, which is limited to regions with low cytomegalovirus seroprevalence, such as Western Europe. In some countries, such as the United States, Finland, and Brazil, nonprimary maternal infections are responsible for most congenital cytomegalovirus health burdens, limiting the potential impact of pregnancy screening. In this invited clinical perspective, we reviewed the evidence and outlined the steps needed to be taken before determining whether the benefits of routine screening for cytomegalovirus in pregnancy outweigh the harms. Until we have the necessary evidence, we should follow the current advice of multiple national health authorities and focus on promoting primary prevention through maternal hygiene precautions.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Hui L, Shand A. Is it time to adopt routine cytomegalovirus screening in pregnancy? No! Am J Obstet Gynecol MFM. 2021. PMID: 33766808. doi:10.1016/j.ajogmf.2021.100355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。